专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060228302A1 Directed complementation 失效
公开(公告)号：US20060228302A1
公开(公告)日：2006-10-12
申请号：US11398171
申请日：2006-04-05
申请人： Murray Robinson , Ronan O'Hagan , Karuppiah Kannan , Ti Cai , Maria Chiu , Lorena Lerner , Jie Lin , Yinghui Zhou
发明人： Murray Robinson , Ronan O'Hagan , Karuppiah Kannan , Ti Cai , Maria Chiu , Lorena Lerner , Jie Lin , Yinghui Zhou
IPC分类号： A61K49/00 , C12N5/06 , C12N15/09
CPC分类号： A01K67/0271 , A01K2217/05 , A01K2217/075 , A01K2227/105 , A01K2267/0331 , C07K14/82 , C12N15/8509 , C12N2830/002
摘要： A method of producing a tumorigenic mouse cell, the tumorigenicity of which depends on a recombinant gene of interest is disclosed. The method involves: (a) providing a conditionally tumorigenic mouse cell containing a recombinant oncogene operably linked to an inducible promoter, wherein (i) expression of the recombinant oncogene is necessary and sufficient for the tumorigenicity of the tumorigenic mouse cell, and (ii) the inducible promoter is in the uninduced state; and (b) introducing into the cell a recombinant gene of interest that functionally complements the oncogene, thereby restoring tumorigenicity without expression of the inducible recombinant oncogene. Also disclosed is a method of testing a compound for anti-tumor effects. The method includes producing tumorigenic mouse cells the tumorigenicity depends on expression of a recombinant gene of interest, implanting the cells in mice and obtaining tumors from the implanted cells, administering test compounds to the mice, and determining anti-tumor effects, if any, of the compounds.

2. 发明授权

US07556796B2 Directed complementation 失效
标题翻译：导向互补
公开(公告)号：US07556796B2
公开(公告)日：2009-07-07
申请号：US11398171
申请日：2006-04-05
申请人： Murray Robinson , Ronan O'Hagan , Karuppiah Kannan , Ti Cai , Maria Isabel Chiu , Lorena Lerner , Jie Lin , Yinghui Zhou
发明人： Murray Robinson , Ronan O'Hagan , Karuppiah Kannan , Ti Cai , Maria Isabel Chiu , Lorena Lerner , Jie Lin , Yinghui Zhou
IPC分类号： A61K49/00 , A61K35/12
CPC分类号： A01K67/0271 , A01K2217/05 , A01K2217/075 , A01K2227/105 , A01K2267/0331 , C07K14/82 , C12N15/8509 , C12N2830/002
摘要： A method of producing a tumorigenic mouse cell, the tumorigenicity of which depends on a recombinant gene of interest is disclosed. The method involves: (a) providing a conditionally tumorigenic mouse cell containing a recombinant oncogene operably linked to an inducible promoter, wherein (i) expression of the recombinant oncogene is necessary and sufficient for the tumorigenicity of the tumorigenic mouse cell, and (ii) the inducible promoter is in the uninduced state; and (b) introducing into the cell a recombinant gene of interest that functionally complements the oncogene, thereby restoring tumorigenicity without expression of the inducible recombinant oncogene. Also disclosed is a method of testing a compound for anti-tumor effects. The method includes producing tumorigenic mouse cells the tumorigenicity depends on expression of a recombinant gene of interest, implanting the cells in mice and obtaining tumors from the implanted cells, administering test compounds to the mice, and determining anti-tumor effects, if any, of the compounds.
摘要翻译：公开了一种致瘤性小鼠细胞的产生方法取决于感兴趣的重组基因的方法。该方法包括：（a）提供含有可操作地连接到诱导型启动子的重组癌基因的条件致瘤小鼠细胞，其中（i）重组癌基因的表达对于致瘤性小鼠细胞的致瘤性是必要和足够的，以及（ii）诱导型启动子处于未诱导状态; 和（b）在细胞中引入功能上补充致癌基因的重组基因，从而恢复致瘤性而不表达可诱导的重组癌基因。还公开了测试化合物抗肿瘤作用的方法。该方法包括产生致瘤性小鼠细胞，其致瘤性取决于感兴趣的重组基因的表达，将细胞植入小鼠中并从植入的细胞中获得肿瘤，向小鼠施用测试化合物，并测定抗肿瘤作用（如果有的话）化合物。

3. 发明申请

US20120231478A1 TIVOZANIB RESPONSE PREDICTION 审中-公开
标题翻译： TIVOZANIB反应预测
公开(公告)号：US20120231478A1
公开(公告)日：2012-09-13
申请号：US13502476
申请日：2010-06-03
申请人： Jie Lin , Bin Feng , Murray Robinson , Feng Jiang , Xiaojian Sun
发明人： Jie Lin , Bin Feng , Murray Robinson , Feng Jiang , Xiaojian Sun
IPC分类号： G01N33/566
CPC分类号： G01N33/57492 , C12Q1/6886 , G01N33/57407 , G01N2333/70596 , G01N2800/52
摘要： A diagnostic method for predicting whether a human tumor will be sensitive or resistant to treatment with tivozanib (AV-951) is disclosed. The method is based on measurement of macrophage content in a tissue sample from a tumor. Measurement of macrophage content can be based on analysis of macrophage marker gene expression, e.g., by RNA analysis or immunohistochemistry.
摘要翻译：公开了一种诊断方法，用于预测人肿瘤是否敏感或对利托那尼治疗有抗药性（AV-951）。该方法基于来自肿瘤的组织样品中巨噬细胞含量的测量。巨噬细胞含量的测定可以基于巨噬细胞标记基因表达的分析，例如通过RNA分析或免疫组织化学。

4. 发明授权

US07736861B1 Tivozanib response prediction 失效
标题翻译： Tivozanib反应预测
公开(公告)号：US07736861B1
公开(公告)日：2010-06-15
申请号：US12645355
申请日：2009-12-22
申请人： Jie Lin , Bin Feng , Murray Robinson , Feng Jiang , Xiaojian Sun
发明人： Jie Lin , Bin Feng , Murray Robinson , Feng Jiang , Xiaojian Sun
IPC分类号： G01N33/53
CPC分类号： G01N33/57492 , C12Q1/6886 , G01N33/57407 , G01N2333/70596 , G01N2800/52
摘要： A diagnostic method for predicting whether a human tumor will be sensitive or resistant to treatment with tivozanib (AV-951) is disclosed. The method is based on measurement of macrophage content in a tissue sample from a tumor. Measurement of macrophage content can be based on analysis of macrophage marker gene expression, e.g., by RNA analysis or immunohistochemistry.
摘要翻译：公开了一种诊断方法，用于预测人肿瘤是否敏感或对利托那尼治疗有抗药性（AV-951）。该方法基于来自肿瘤的组织样品中巨噬细胞含量的测量。巨噬细胞含量的测定可以基于巨噬细胞标记基因表达的分析，例如通过RNA分析或免疫组织化学。

5. 发明授权

US07615353B1 Tivozanib response prediction 失效
标题翻译： Tivozanib反应预测
公开(公告)号：US07615353B1
公开(公告)日：2009-11-10
申请号：US12498183
申请日：2009-07-06
申请人： Jie Lin , Murray Robinson , Bin Feng , Wenping Kathryn Sun
发明人： Jie Lin , Murray Robinson , Bin Feng , Wenping Kathryn Sun
IPC分类号： C12Q1/68 , C12P19/34 , C07H21/04
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/158
摘要： A diagnostic method for predicting quantitatively whether a human tumor will be responsive or resistant (non-responsive) to treatment with the VEGF inhibitor, tivozanib (AV-951), is disclosed. The test is based on application of an algorithm to measurements of expression levels of the genes in a predictive gene set.
摘要翻译：公开了一种诊断方法，用于定量地预测人肿瘤是否对VEGF抑制剂替利扎布（AV-951）的治疗具有响应性或抗性（非响应性）。该测试基于将算法应用于预测基因组中基因表达水平的测量。

6. 发明申请

US20140122190A1 SYSTEM AND METHODS FOR DETECTION AND SELECTION OF A RESOURCE AMONG AVAILABLE RESOURCES 审中-公开
标题翻译：用于检测和选择可用资源资源的系统和方法
公开(公告)号：US20140122190A1
公开(公告)日：2014-05-01
申请号：US14068307
申请日：2013-10-31
申请人： Ouri Wolfson , Leon Stenneth , Bo Xu , Daniel Ayala , Bhaskar DasGupta , Jie Lin
发明人： Ouri Wolfson , Leon Stenneth , Bo Xu , Daniel Ayala , Bhaskar DasGupta , Jie Lin
IPC分类号： G08G1/14 , G07B15/00
CPC分类号： G08G1/144 , G06Q10/0631 , G07B15/00 , G08G1/141
摘要： Detecting whether a resource is available and facilitating the selection of a resource from a set of resources, some of which may be available or unavailable at any given time can be a challenge. One such resource is a suitable place to park a vehicle including automobile, motorcycle, and bicycle. Finding parking can be a significant challenge in population dense environments. Certain embodiments of the present invention are configured to assist users with quickly and efficiently finding a parking slot near his or her location or destination. The system may be configured to generate parking slot suggestions based on one or more of a wide range of individual or group preference criteria. Advantageously, facilitating quick and efficient parking reduces traffic congestion and pollution.
摘要翻译：检测资源是否可用并且便于从一组资源中选择资源，其中一些资源可能在任何给定时间可用或不可用是一个挑战。一个这样的资源是停放包括汽车，摩托车和自行车在内的车辆的合适的地方。在人口密集的环境中寻找停车是一个重大的挑战。本发明的某些实施例被配置为帮助用户快速有效地在他或她的位置或目的地附近找到停车槽。该系统可以被配置为基于广泛范围的个人或组偏好标准中的一个或多个来产生停车槽建议。有利地，促进快速和高效的停车减少交通拥堵和污染。

7. 发明授权

US08580930B2 Hepatocyte growth factor (HGF) binding proteins 有权
公开(公告)号：US08580930B2
公开(公告)日：2013-11-12
申请号：US13589664
申请日：2012-08-20
申请人： William M. Winston, Jr. , S. Kirk Wright , May Han , Lyne Breault , Jie Lin , Bijan Etemad-Gilbertson , Christine Knuehl , Jeno Gyuris , Arnold Horwitz
发明人： William M. Winston, Jr. , S. Kirk Wright , May Han , Lyne Breault , Jie Lin , Bijan Etemad-Gilbertson , Christine Knuehl , Jeno Gyuris , Arnold Horwitz
IPC分类号： C07K16/24 , C07K16/00
CPC分类号： C07K16/22 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.

8. 发明申请

US20120252829A1 TIVOZANIB AND CAPECITABINE COMBINATION THERAPY 审中-公开
标题翻译： TIVOZANIB和CAPECITABINE组合治疗
公开(公告)号：US20120252829A1
公开(公告)日：2012-10-04
申请号：US13436021
申请日：2012-03-30
申请人： Jie Lin , Jeno Gyuris , Feng Jiang , Guangmu Li , Xiaojian Sun
发明人： Jie Lin , Jeno Gyuris , Feng Jiang , Guangmu Li , Xiaojian Sun
IPC分类号： A61K31/513 , A61P35/00
CPC分类号： A61K31/4709 , A61K31/7068 , A61K2300/00
摘要： A method of treating a tumor in a subject using a combination of tivozanib and capecitabine is disclosed.
摘要翻译：公开了一种使用噻替尼和卡培他滨组合治疗受试者的肿瘤的方法。

9. 发明申请

US20110228338A1 SYSTEM AND METHOD FOR DEVELOPING A PRINT SHOP CONFIGURATION 有权
标题翻译：用于开发打印店配置的系统和方法
公开(公告)号：US20110228338A1
公开(公告)日：2011-09-22
申请号：US13150524
申请日：2011-06-01
申请人： David Snyderman , Timothy W. Jacobs , Jie Lin
发明人： David Snyderman , Timothy W. Jacobs , Jie Lin
IPC分类号： G06F3/12
CPC分类号： G06Q10/06 , G06Q10/06311
摘要： A system is provided for forming a print shop configuration with a first set of equipment, the first set of equipment being derived from a second set of equipment from a first print shop and a third set of equipment from a second print shop. The system includes a manager and application, the manager and application working together to generate a list of at least some of all possible print shop configurations that could be formed with a selected number of cells. The cells are populated with selected pieces of equipment from the second and third sets of multiple pieces of equipment. A criterion is used to select, from the list of possible print shop configurations, the print shop configuration with the first set of equipment.
摘要翻译：提供了一种用于形成具有第一组设备的印刷车间配置的系统，所述第一组设备从第二印刷车间从第一印刷车间和第三组设备衍生自第二组设备。系统包括管理者和应用程序，管理者和应用程序一起工作以产生可以用选定数量的单元格形成的所有可能的打印店配置中的至少一些的列表。从第二组和第三组多件设备中选出的设备的细胞填充。使用标准从可能的印刷车间配置的列表中选择具有第一组设备的印刷车间配置。

10. 发明授权

US07943344B2 Hepatocyte growth factor (HGF) binding proteins 有权
标题翻译：肝细胞生长因子（HGF）结合蛋白
公开(公告)号：US07943344B2
公开(公告)日：2011-05-17
申请号：US12632765
申请日：2009-12-07
申请人： William M. Winston, Jr. , S. Kirk Wright , May Han , Lyne Breault , Jie Lin , Bijan Etemad-Gilbertson , Christine Knuehl , Jeno Gyuris , Arnold Horwitz
发明人： William M. Winston, Jr. , S. Kirk Wright , May Han , Lyne Breault , Jie Lin , Bijan Etemad-Gilbertson , Christine Knuehl , Jeno Gyuris , Arnold Horwitz
IPC分类号： C12P21/08 , C07H21/04 , C12N15/63 , C12N5/10
CPC分类号： C07K16/22 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
摘要翻译：本发明提供结合并中和肝细胞生长因子（HGF），特别是人HGF的活性的结合蛋白家族。结合蛋白可用作诊断和/或治疗剂。关于它们的治疗活性，结合蛋白可用于治疗某些HGF应答性病症，例如某些HGF反应性肿瘤。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式